Work

Crizotinib in patients (pts) with MET-amplified non-small cell lung cancer (NSCLC): Updated safety and efficacy findings from a phase 1 trial.

Year: 2018

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2018.36.15_suppl.9062

Authors: D. Ross Camidge, Gregory Alan Otterson, Jeffrey W. Clark, Sai-Hong Ignatius Ou, Jared Weiss, Steven Ades, Umberto Conte, Yiyun Tang, Sherry Chia-E Wang, Danielle Murphy, Keith D. Wilner, Liza Cosca Villaruz

Institutions: University of Colorado Anschutz, The Ohio State University, Massachusetts General Hospital, University of California, Irvine, University of North Carolina at Chapel Hill, University of Vermont Medical Center, Pfizer (United States), University of Pittsburgh Medical Center

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2887029617

Cites:

Cited by: 80

Related to: 10